330 results on '"Pradier, Laurent"'
Search Results
2. LRP1 Has a Predominant Role in Production over Clearance of Aβ in a Mouse Model of Alzheimer’s Disease
3. Reporter cell assay for human CD33 validated by specific antibodies and human iPSC-derived microglia
4. Chapitre 7 : Maladie d’Alzheimer et cibles thérapeutiques : état de l’art
5. BIN1 recovers tauopathy-induced long-term memory deficits in mice and interacts with Tau through Thr348 phosphorylation
6. Alzheimer's disease-associated R47H TREM2 increases, but wild-type TREM2 decreases, microglial phagocytosis of synaptosomes and neuronal loss
7. Participating in innovative medicines initiative funded neurodegenerative disorder projects—An impact analysis conducted as part of the NEURONET project
8. SAR110894, a potent histamine H3-receptor antagonist, displays disease-modifying activity in a transgenic mouse model of tauopathy
9. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)
10. Alzheimer's disease‐associated R47H TREM2 increases, but wild‐type TREM2 decreases, microglial phagocytosis of synaptosomes and neuronal loss
11. The Innovative Medicines Initiative neurodegeneration portfolio: From individual projects to collaborative networks
12. Systemic immune‐checkpoint blockade with anti‐PD1 antibodies does not alter cerebral amyloid‐β burden in several amyloid transgenic mouse models
13. Novel potent liposome agonists of triggering receptor expressed on myeloid cells 2 phenocopy antibody treatment in cells
14. Alzheimer's disease-associated R47H TREM2 increases, but wild-type TREM2 decreases, microglial phagocytosis of synaptosomes and neuronal loss.
15. No replication of genetic association between candidate polymorphisms and Alzheimer's disease
16. A calcium-sensitive antibody isolates soluble amyloid-β aggregates and fibrils from Alzheimer’s disease brain
17. The Innovative Medicines Initiative neurodegeneration portfolio: From individual projects to collaborative networks.
18. A Novel Selective PKR Inhibitor Restores Cognitive Deficits and Neurodegeneration in Alzheimer Disease Experimental Models
19. Altered cerebral vascular volumes and solute transport at the blood–brain barriers of two transgenic mouse models of Alzheimerʼs disease
20. Tetravalent Bispecific Tandem Antibodies Improve Brain Exposure and Efficacy in an Amyloid Transgenic Mouse Model
21. Impact of aging: Sporadic, and genetic risk factors on vulnerability to apoptosis in Alzheimer’s disease
22. The PKR Activator PACT Is Induced by Aβ: Involvement in Alzheimerʼs Disease
23. Gene delivery of a modified antibody to Aβ reduces progression of murine Alzheimer’s disease
24. ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease
25. Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice
26. Antibody-bound β-amyloid precursor protein stimulates the production of tumor necrosis factor-α and monocyte chemoattractant protein-1 by cortical neurons
27. Innervation of senile plaques
28. Amyloid β-induced Changes in Nitric Oxide Production and Mitochondrial Activity Lead to Apoptosis
29. mTOR/p70S6k signalling alteration by Aβ exposure as well as in APP-PS1 transgenic models and in patients with Alzheimerʼs disease
30. Expression of human FE65 in amyloid precursor protein transgenic mice is associated with a reduction in β-amyloid load
31. Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1
32. Time sequence of maturation of dystrophic neurites associated with Aβ deposits in APP/PS1 transgenic mice
33. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse
34. The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration
35. Intraneuronal APP/Aβ Trafficking and Plaque Formation in β-Amyloid Precursor Protein and Presenilin-1 Transgenic Mice
36. The caspase-derived C-terminal fragment of βAPP induces caspase-independent toxicity and triggers selective increase of Aβ42 in mammalian cells
37. Effects of the level of mRNA expression on biophysical properties, sensitivity to neurotoxins, and regulation of the brain delayed-rectifier K+ channel Kv1.2
38. The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates
39. Cloning of Rat Parkin cDNA and Distribution of Parkin in Rat Brain
40. Additional file 2: of SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)
41. Differential Screening of Mutated SOD1 Transgenic Mice Reveals Early Up-Regulation of a Fast Axonal Transport Component in Spinal Cord Motor Neurons
42. BIN1 recovers tauopathy-induced long-term memory deficits in mice and interacts with Tau through Thr348 phosphorylation
43. NFL in CSF and serum, a potential translational dynamic biomarker of neurodegeneration in preclinical models
44. P1‐106: A HEAD‐TO‐HEAD COMPARISON OF LEAD CLINICAL ANTI‐Aβ ANTIBODIES
45. Mapping the APP/Presenilin (PS) Binding Domains: The Hydrophilic N-Terminus of PS2 Is Sufficient for Interaction with APP and Can Displace APP/PS1 Interaction
46. Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models
47. NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration
48. ANTI-AMYLOID ANTIBODIES AS A POTENTIAL THERAPEUTIC FOR ALZHEIMER’S DISEASE: NEUROPROTECTIVE ACTIVITY OF SAR228810 AGAINST AMYLOID-INDUCED NEUROTOXICITY IN VITRO
49. BIN1 recovers tauopathy-induced long-term memory deficits in mice and interacts with Tau through Thr348 phosphorylation.
50. Axonal degeneration in an Alzheimer mouse model is PS1 gene dose dependent and linked to intraneuronal Aβ accumulation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.